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Abstract
Currently, more than 90% of compounds identified are water insoluble and or poorly
water soluble, which is a bottle neck in the development of many new drug candidates.
These poorly soluble  drug molecules  are  difficult  to  formulate  using conventional
approaches and are associated with numerous formulation‐related performance issues.
Formulating these compounds using lipid‐based systems is one of the rapidly growing
interests  and  suitable  drug  delivery  strategies.  Lipid  formulations  such  as  self‐
emulsifying/microemulsifying/nanoemulsifying  drug  delivery  systems  (SEDDS/
SMEDDS/SNEDDS) have been attempted in many researches to improve the bioavail‐
ability and dissolution rate for their better dispersion properties. One of the greatest
advantages of incorporating the poorly soluble drug into such formulation products is
their spontaneous emulsion and or microemulsion/nanoemulsion formation in aqueous
media. The performance and ongoing advances in manufacturing technologies have
rapidly introduced lipid‐based drug formulations as commercial  products into the
marketplace with several others in clinical development. The current chapter aims to
present  the  characteristics  feature,  development  and utilization of  oral  lipid‐based
nanoformulations within the drug delivery regime. The content of the chapter also
provides an insight into the in vitro evaluation of lipid‐based nanosystems and their
limitations.
Keywords: lipid‐based formulation, self‐nanoemulsifying drug delivery systems
(SNEDDS), poorly water soluble drugs (PWSDs), lipid formulation classification sys‐
tems (LFCS), solubility enhancement
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1. Introduction
Due to the continuous rise in the number of low solubility drug molecules and lack of more
targeted drug therapies, the drug development has become more complex and challenging
job within the industry. In fact, up to 90% of today's drug candidates are suffering from low
aqueous solubility, which is commonly associated with low bioavailability, high intra‐ and
inter‐subject variability and lack of dose suitability [1, 2]. In keeping these challenges in mind,
drug  formulators  must  seek  new  techniques  and  innovative  formulation  approaches  to
overcome such hurdles and ensure effective treatments for the patients in need.
It is more than a decade, when lipid‐based formulations have been considered as a well‐
established strategy for improving oral bioavailability and minimizing variable food effect of
poorly soluble compounds. Lipids have been used as carriers in various delivery systems for
drug administration, including solutions, suspensions, emulsions, and more attractively self‐
emulsifying/microemulsifying/nanoemulsifying drug delivery systems (SEDDS/SMEDDS/
SNEDDS) that are designed to increase solubility and bioavailability of drugs belonging to the
BCS Class II–IV [3]. Among several approaches, which are currently available to incorporate
active pharmaceutical drugs into lipid vehicles in a variety of dosage forms, SEDDS, SMEDDS
and or SNEDDS have proved to be the most successful approaches in improving the bioavail‐
ability [4]. The initial key achievement of these formulation systems (SEDDS/SMEDDS/
SNEDDS) is to increase the solubilization of the poorly water soluble drugs (PWSDs) by the
formation of emulsions and or micellar systems (colloidal solutions).
These systems advantageously present the drug in solubilized form, and their relatively
smaller droplet sizes provide a large interfacial area enhancing the activity of pancreatic lipase
to hydrolyze triglycerides and thereby promoting faster drug release containing mixed
micelles of bile salts. The development of Neoral® (cyclosporin A) as a commercial product
exhibits an excellent example of the utilization of these systems [5].
Nanotechnology has become a buzzword for scientific experts, and efforts are ongoing to
extend its applications in various medical and pharmaceutical aspects. The nanoscale tech‐
nologies can be generally categorized into: lipid‐based nanocarriers, polymeric nanocarriers,
inorganic nanocarriers, and drug nanoparticles or nanosuspensions [6]. Within the lipid‐based
nanocarriers category, there has been a resurgence of interest in nanoemulsions since low
energy emulsification methods, such as spontaneous or self‐nanoemulsification, have been
developed. SNEDDS are anhydrous homogenous liquid mixtures, composing oil, surfactant,
drug and/or cosolvents, which spontaneously form transparent nanoemulsion (20–250 nm
droplet size) upon aqueous dilution with mild agitation [6, 7].
Being nanosized, SNEDDS offer a strong alternative to the more conventional oral formula‐
tions of lipophilic compounds. SNEDDS introduce the drug in solution within nanosized oil
droplets. These fine droplets are emptied rapidly from the stomach resulting in faster drug
release all over the gastrointestinal (GI) tract. An additional advantage of SNEDDS over simple
oily solutions is granting much larger interfacial area for partitioning of the drug between oil
and water leading to ease of dispersibility [8]. In contrast to oily solutions, SNEDDS does not
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depend on the action of bile salts, enzymes and/or other effects related to the (fed/fasted) state
of the stomach [9]. Thus, SNEDDS can reduce the variability in rate and extent of absorption
and grant more reproducible plasma concentration levels [10].
Compared with conventional nanoemulsions, SNEDDS can offer the advantages of improved
physical and/or chemical stability of the formulation and ability to fill them into unit dosage
forms, such as soft/hard capsules, which improve their commercial viability, patient compli‐
ance/tolerability and reduce palatability‐related concerns [6]. A key feature of a successful
SNEDDS formulation is its capability to hold the drug in solution, throughout the GIT, for
sufficient time to allow for absorption [11]. Many PWSDs have high solubility in SNEDDS
formulations but could make a risk of precipitation after aqueous dispersion of the formulation
or during its digestion in the intestine [12].
The current chapter will provide all the information to probe factors which influence the
selection of successful lipid nanoformulations and affect the fate of the PWSDs after oral
administration. The investigational research presented in this chapter will also provide
additional information regarding current practice of lipid formulations with a particular
emphasis on self‐nanoemulsifying drug delivery systems (SNEDDS), the trends and perspec‐
tives and the fate of PWSDs formulated in SNEDDS.
2. Lipid nanoformulations: design approach
Lipid excipients are comprised of a large group of physically and chemically diverse glycer‐
ides, which may be used in simple (single oil solutions of the drug substance) or in more
complex nanocarriers (SMEDDS/SNEDDS, drug dissolved in the mixture of glyceride,
surfactant and or cosolvent), with considerable flexibility in formulation design [12].
Simple oil formulations are generally composed of mono‐, di‐, or triglycerides or their
derivatives and differ on the content of medium‐ (C6‐C10 in chain length) or long‐chain (C12‐
C24 in chain length) fatty acids. Glyceride esters are water immiscible, and their solvent
capacities for drug substances vary according to the fatty acid chain length. Many lipid
excipients (oils, surfactants), which are regarded as acceptable food grade materials, expected
to be well tolerated by the body [13], even as parenteral emulsion dosage form [14]. These
excipients have a history of use in a wide variety of pharmaceuticals.
In simple terms, lipid nanoformulations can be distinguished according to their dispersion
and digestion in the aqueous content of the gut [15, 16]. Emulsion droplet size has been
considered to be an important part in the performance of self‐nanoemulsifying systems since
particle size can determine the rate and extent of drug release in vitro [17]. However, the relative
digestion rate would be expected to vary if the formulation is modified, and the critical factor
is the fate of the drug after digestion of the formulation, in particular whether or not the drug
remains in a solubilized state.
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Func‐
tion 
Composition and description  Commercial name  Supplier 
Oil  Medium‐chain triglycerides (C8‐C10): Fractio‐
nated coconut oil and palm seed oil, triglycer‐
ides of caprylic/capric acid 
Miglyol 812, 810, Capmul
MCM, Captex 355, etc. 
Gattefosse corporation,
France; Abitec Corp.,
Janesville, USA;
Sasol GmbH, Witten,
Germany; Nikko Chemicals Co.,
Tokyo, Japan;
Cremer Oleo GmbH & Co. KG,
Hamburg, Germany;
Lipoid, Germany; BASF Co.,
Germany 
Long‐chain triglycerides (C14‐C22):
Vegetable oils are glyceride esters of mixed
unsaturated long‐chain fatty acids, commonly
known as long‐chain
triglycerides 
Soybean oil, sesame oil,
corn oil, olive oil,
peanut oil, cottonseed oil,
rapeseed oil, etc. 
Mixed mono‐, di‐ and triglycerides:
Novel semisynthetic medium‐ and
long‐chain derivatives. Esters of propylene
glycol and mixture of mono‐ and diglycerides
of caprylic/capric acid 
Imwitor 988, Imwitor 308,
Maisene 35‐1, etc. 
Polar oil: Some excipients which are
traditionally thought of as hydrophobic
surfactants, such as sorbitan fatty acid
esters 
Span 80, 85, etc. 
Nonionic
surfac‐
tant  
Water insoluble: Oleate esters, such as poly‐
oxyethylene (20) sorbitan trioleate, PEG‐6‐sor‐
bitan oleate and polyoxyethylene (25) glyceryl
trioleate are commonly used in the pharma‐
ceutical
industries 
Polysorbate 85 (Tween 85),
TO‐106 V, Tagat TO, etc. 
Water soluble: The popular castor oil
derivatives with saturated alkyl chains result‐
ing from hydrogenation of materials derived
from a vegetable oil. Other
derivatives include polysorbate 80 which are
predominantly ether ethoxylates and
phospholipids 
Cremophor RH40, Cremo‐
phor EL, HCO30, Tween
20, 80, poloxamer 407, vari‐
ous Labrasols, Labrafac
Labrafils, Gelucires, Soy
phosphatidylcholine, etc. 
Cosol‐
vent 
The most popular water soluble cosolvents
are propylene glycol, polyethylene glycol,
ethanol and glycerol. Others are diethylene
glycol monoethyl ether,
propylene carbonate, tetrahydrofurfuryl
alcohol, polyethylene glycol ether 
PG, PEG 300, PEG 400, 600,
transcutol, glycofurol,
etc. 
Other
exci‐
pient 
Many oil‐soluble antioxidants  α‐Tocopherol, β‐carotene,
butylated hydroxytoluene
(BHT), butylated hydrox‐
yanisole (BHA), propyl gal‐
late, ascorbyl palmitate,
etc. 
Table 1. Common excipients for designing self‐nanoemulsifying formulations and the list of their suppliers.
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2.1. Excipients used to design lipid‐based nanoformulations
Excipients play a key role in designing successful nanoformulations with a sound control
strategy and influence business‐critical and clinically significant drug product performance
outcomes such as stability, bioavailability and manufacturability. The design of lipid‐based
nanoformulations, particularly SNEDDS, is comparatively simple as the drug need to be
incorporated into a suitable oil‐surfactant mixture, which could be filled in a soft or hard gelatin
capsules. Various choices of lipid excipients are available in the market. Numerous lipids are
amphiphilic in nature, which contain both hydrophilic and lipophilic portions (fatty acid) [18].
The morphology of the lipids should be assessed as melting point increases when the length
of fatty acid chain increases, but it decreases when unsaturation of the fatty acid increases [19].
Choice of excipients for successfully designed lipid‐based nanocarriers is determined based
on factors, such as miscibility; solvent capacity; self‐dispersibility; digestibility; irritancy;
toxicity; purity; chemical stability; compatibility with capsule; melting point; and cost. Since
these excipients can affect the drugs bioavailability, it is necessary to identify the characteristics
of these excipients. Details of the lipids (oils, nonionic surfactants, cosolvents), their compo‐
sitions and list of suppliers are given in Table 1.
3. Lipid nanocarriers and recent advancements in oral drug delivery
Lipid‐based nanoformulations as drug delivery vehicles signify a promising strategy that
incorporates or encapsulates the drug molecules and are biodegradable or biocompatible. They
are containing nanosized droplets typically ranging from 0 to 250 nm [20]. The entrapped drug
molecules can be taken intact and protected against degradation by gastrointestinal (GI) fluids,
while drug absorption through the GI epithelium or lymphatic transport can be enhanced.
Possible mechanisms of transport of these nanocarriers across GI mucosa are introduced later
in the chapter. These focus on effects of size and surface properties of the nanocarriers on the
nonspecific or targeted uptake by enterocytes and/or M cells. Applications of various oral
nanocarrier formulations, such as lipid nanoparticles and SMEDDS/SNEDDS, are reviewed in
several recent publications [4, 21, 22]. Figure 1 shows an encapsulated SNEDDS designed for
oral administration, which are the most efficient formulations for improving the apparent
aqueous solubility of PWSDs.
Within the scope of the current chapter, the most advanced SNEDDS and/or SMEDDS systems
have been explored as potential nanocarriers, which are much more stable kinetically and
thermodynamically and showed great potential for improving the bioavailability of orally
administered drugs. In a pure drug nanoparticle formulation, submicron size particles of drugs
are stabilized in aqueous medium with generally regarded as safe (GRAS) listed excipients
blend. Such formulation can be used for drugs with poor solubility in water and oil, high
melting point, high log P and high dose.
When saquinavir (HIV protease inhibitor) in 1995 was marketed for the first time as mesylate
salt formulation in a hard gelatin capsule (Invirase®), its bioavailability was only 4% and highly
variable [23]. Later on, after 2 years, a self‐nanoemulsifying formulation of saquinavir (Forto‐
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vase®) containing medium‐chain mono‐ and diglycerides, povidone and α‐tocopherol was able
to increase bioavailability threefold higher than Invirase® in humans [23, 24]. Several other
published [10, 25, 26] and unpublished case studies are also available that established the
significance of rational approach in designing SMEDDS/SNEDDS which can improve the in
vivo absorption of the PWSDs. The commercial product such as amprenavir (agenerase),
ciprofloxacin (cipro), fenofibrate (fenogal), liponavir/ritonavir (kaletra, norvir), etc., have been
formulated using suitable SMEDDS/SNEDDS [24, 27].
Figure 1. The encapsulated SNEDDS designed for oral administration of PWSDs. *Adapted with permission from Ref.
[21].
4. Concept of nanoemulsions within lipid‐based formulation
The potentiality of nanoemulsions within lipid‐based drug delivery systems was explored
almost four decades ago. In simple term, nanoemulsions are the emulsions comprising
nanosized droplets and they are well dispersed, transparent and kinetically stable for several
months. Their physical stability can be improved by careful selection of surfactants and the
ratio of oil/water/surfactant and also the efficiency of equipment used to reduce droplet sizes.
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Not only for oral delivery, nanoemulsions are used as greater transmucosal and transdermal
drug delivery vehicles due to their remarkable wetting, spreading and penetration abilities.
4.1. SMEDDS vs SNEDDS
SMEDDS and SNEDDS are almost similar lipid dosage form which can be prepared from same
materials comprising a simple mixture of oils, surfactants and possibly cosolvents. SMEDDS
have the ability to form fine oil in water (O/W) microemulsion, and SNEDDS produce
nanoemulsion upon mild agitation in the presence of an aqueous (preferably intestinal) media
[28]. The structure provides both SMEDDS and SNEDDS as good candidates for oral delivery
of PWSDs with adequate solubility in oil only or oil/surfactant blends and establishes the
desired reproducible pharmacokinetic profile. Upon dilution, SMEDDS form transparent
microemulsions, with a droplet size of <50 nm [11], while SNEDDS produce transparent
dispersions of oil and water stabilized by surfactants, with droplet sizes between 20 and 250 
nm and kinetically but not thermodynamically stable systems [29]. These two systems are the
most famous colloidal dispersions within lipid‐based systems but physicochemically different.
Structures and properties of nanoemulsion can be changed on long‐term storage but not for
microemulsions at same temperature, pressure and composition. The formation of SMEDDS
is spontaneous, and SNEDDS need high‐energy methods for their fabrication, but both systems
need some external energy to overcome kinetic energy barriers and support mass transport.
In comparison, SNEDDS need lesser surfactant‐to‐oil ratio than SMEDDS. The preparation of
SNEDDS involve specific mixing order in which surfactant must be mixed first with oil phase,
whereas SMEDDS do not need any specific mixing order for their preparation. Ternary phase
diagrams are required to have a suitable selection of both systems which should be coherent
with different phases involved in preparation.
An important best‐known example is Sandimmune Neoral® which was introduced in 1994
became the turning point for development of SMEDDS in oral lipid‐based formulations of
PWSD [30]. This formulation contains Cremophor RH40 (polyoxyl hydrogenated castor oil),
corn oil glycerides, propylene glycol and ethanol, which emulsifies spontaneously into a
microemulsion with a particle size smaller than 100 nm. This new formulation (Sandimmune
Neoral®) resulted in a twofold increase in the bioavailability compared to the earlier product
Sandimmune® [31]. Recent years, SMEDDS and SNEDDS have gained lots of interest as
potential drug delivery vehicles largely due to their clarity, simplicity of preparation, thermo‐
dynamic stability and their abilities to be filtered and to incorporate a wide range of drugs of
varying lipophilicity.
4.1.1. SMEDDS/SNEDDS within lipid formulation classification systems
By considering several factors in mind, Pouton [20, 32] introduced a lipid formulation
classification system (LFCS) into four Types (I–IV) which differentiate lipid‐based formula‐
tions from one to another that is being used as a framework to categorize nanoformulations.
These four Types of formulations were classified on the basis of formulation compositions,
their aqueous dispersibility and the potential effects of lipid digestion and possible drug
precipitation from lipids. Among the LFCS, Type III systems are the most attractive formula‐
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tions as they produce microemulsions/nanoemulsions (SMEDDS and SNEDDS) of lipid‐
surfactant mixtures with particle sizes in the range of 0–250 nm upon dispersion. The
microemulsions can be used for many other drug delivery/application systems, such as topical,
intra venous, trans‐dermal, etc. There are several marketed products available which were
developed as Type III formulations since the drugs may be absorbed from the microemulsions
and or nanoemulsions without the digestion of lipids and/or surfactants present. Type III
systems further divided into subtype IIIA and IIIB according to the hydrophilic content of the
SMEDDS and SNEDDS. Type IV systems are efficient formulations as they also produce
SMEDDS and/or SNEDDS and have high drug loading ability but may loss solvent capacity
upon dilution with aqueous media.
4.2. Solidification of SMEDDS/SNEDDS
The excipients commonly used in designing SNEDDS are liquid at room temperature, and
their compatibility with semi‐solid and solid dosage forms allows encapsulating into soft/hard
gelatin capsules for oral delivery. This could be a great challenge as the interaction between
liquid formulation and capsule shell may result in either brittleness or softness of the shell [33].
In addition, the stability of liquid formulations could be another major issue (e.g., leaching and
rancidity) since some drugs might suffer significant chemical instability in both aqueous and
oily formulations. Apart from that, manufacturing liquid‐filled soft gelatin capsules is a slow
process and requires specialized equipment, having risk of formulation components migrating
into capsule shell [23].
Therefore, to address this limitation, incorporation of liquid lipid formulations into a solid
dosage form is convincing and desirable. Liquid lipid formulations could be transformed into
acceptable free flowing fine powder by loading the formulation on a suitable solid carrier as
solid SNEDDS [34, 35]. Only few studies have attempted to investigate the conversion of such
formulations into free flowing powders by adsorption using various inorganic high surface
area materials (i.e., neusilin, syloid, aeroperal and aerosol) that are amenable to encapsulation
or tableting [36, 37]. On the other hand, the final powder preparation should have acceptable
flow properties to achieve the best content uniformity and weight variation. The current
interest in solidification technique by both the industry and academia is raised enormously
due to the attractive properties including independence of gastric transit, flexibility in dose
dividing, decrease in intra‐ and inter‐subject variability, highest safety profile and physical/
chemical stability improvement.
5. Equilibrium solubility of diluted nanoformulations
For lipid nanoformulations, drug solubility determines the maximum drug loading capacity
(single unit dose) and is increased when the drug is highly lipid soluble or when the formu‐
lation contains high proportions of surfactant or cosolvent. The solubilization capacity of the
nanoformulations (SNEDDS) is likely to decrease when excipients are dispersed and digested
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in the GI tract. As a result, the drug concentrations in the GI fluids are elevated from the
equilibrium solubility and could cause extreme precipitation.
To predict the likely fate of the drug on dispersion effectively, one should investigate its
solubility in the formulations during aqueous dilution. The solubility of PWSDs within the
diluted nanoformulations can be determined using a shake‐flask method to observe how the
drug solubility is changed as water is incorporated into the system. The samples are prepared
by adding an excess amount of drug to the formulation, which is then shaken and thoroughly
mixed with a vortex mixer. The samples are incubated in a dry heat incubator at 37°C for 7 
days and centrifuged to separate excess solid drug from the dissolved drug. An aliquot of the
supernatant is weighed and diluted in an appropriate solvent. The dissolved drug concentra‐
tion can be analyzed by UV‐vis spectrophotometer.
Figure 2. Effect of aqueous dilution on solubility of fenofibrate in nanoformulations representing LFCS Types IIIB and
IV systems. Data are presented as mean ± SD (n = 3).
Figure 2 shows the fenofibrate solubility in nanoformulations (SMEDDS/SNEDDS) of LFCS
Type IIIB and IV systems which was studied over 10–100 dilution with water. The results
suggest how fenofibrate solubility decreased markedly, with several Type IIIB and IV nano‐
formulations, as the formulation was diluted with water [12]. After adding only 10% w/w water
to the anhydrous formulation (drug dissolved at 80% of its equilibrium solubility), the one‐
third drug solubility had dropped down from the initial solubility of the formulation. The data
predict that if fenofibrate was dissolved at its equilibrium solubility in the anhydrous formu‐
lations, its solubility would be exceeded in all cases when the formulation is diluted 1 in 10 or
1 in 100.
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6. Drug release and the justification of dispersion test for nanoformulations
In vitro release studies assess the ability of lipid‐based nanoformulations to disperse into
various types of media and to evaluate whether the drug partitions from the vehicle into the
aqueous medium. It can estimate how much drug will be in solution before absorption thus
predicts the fate of the drug in vivo. A range of biorelevant dissolution test media and experi‐
mental methodologies has been developed by Dressman's group that have established
application in drug release studies from lipid‐based oral formulations [38, 39].
Technically, it is difficult to characterize drug release from emulsions in vitro, particularly under
sink condition. Since solubility of the drug in sink phase may be poor, large volumes of aqueous
content may be needed to maintain the sink conditions. It is hard to separate the oil droplets
due to their smaller size from the dissolved or released drug in the sink solution levy. In a
previous study, our group has conducted an in vitro dissolution of anti‐histaminic drug,
cinnarizine (CN, week base) from various SNEDDS systems and commercial product Stuger‐
on® tablet [4]. Dissolution was carried out in simulated gastric fluid (SGF, pH 1.2) for first 2 h
and subsequently shifted into simulated intestinal fluid (SIF, pH 6.8) for another 2 h.
Figure 3. Dissolution profiles of cinnarizine SNEDDS 1 [MCT/MCDM/T85 (25/25/50)], SNEDDS 2 [MCT/MCM/T85
(25/25/50)] and Stugeron® tablets. Data are expressed as mean ± S.E, n = 3. **Abbreviations: MCT—medium‐chain tri‐
glycerides (M810); MCDM—mixture of medium‐chain di‐ and monoglycerides (I988); MCM—medium‐chain mono‐
glycerides (I308); T85—Tween 85.
In SGF, all the SNEDDS showed superior dissolution profiles with respect to Stugeron® tablet
(Figure 3). At 15 min, Stugeron® tablet managed to release only 66.5% drug in solution where
the optimal formulations were able to release 84–95% drug in solution. This indicates the ability
of these formulations to provide more efficient and rapid release of CN with respect to the
marketed tablet. Upon shifting from SGF to SIF, Stugeron® showed significant precipitation
(87–92% precipitated), while the SNEDDS were able to hold high amount of CN (78–93%) in
solution (Figure 3). This finding suggests the immense need for developing a SNEDDS that
could enhance the drug dissolution profile and resist the sharp pH‐dependent changes
particularly for week bases.
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A standard USP dissolution apparatus is suitable for the establishment of a dispersion test, but
emphasis should be on precipitation rather than dissolution [4]. This is why, dynamic disper‐
sion test is highly considered for the prediction of whether precipitation is likely to occur prior
to digestion. In the dispersion study, samples are removed from the dispersion vessel at various
intervals for at least 24 h and analyzed to determine the likelihood of precipitation during GI
transit. Dispersion testing is vital for LFCS Types III and IV formulations (produce SNEDDS),
which may loss solvent capacity on dispersion due to migration of water soluble components
into the bulk aqueous phase. Care is needed in the design of lipid‐based nanoformulations to
ensure that the precipitation of the drug is minimized.
7. Mechanism of drug supersaturation: role of SMEDDS/SNEDDS
When the lipid nanoformulations approach to the high volume of gastric fluid, it is dispersed
rapidly and reduces solubilization capacity of the drug due to the high content of surfactant/
water soluble cosolvent, thus potentially generates supersaturation. Even though supersatu‐
ration in the stomach is not desirable as most of the drugs are absorbed in the small intestine,
it poses threat for drug precipitation before the drug enters to small intestine. Therefore,
SMEDDS/SNEDDS should be designed to minimize supersaturation in the stomach or at least
to maintain a period sufficient to allow gastric emptying prior to drug precipitation.
Correlations between the investigations of the equilibrium solubility of the drug in the aqueous
diluted formulation (10–99% diluted) and corresponding dynamic dispersion tests could help
to predict whether precipitation is likely to take place, and whether it would affect bioavaila‐
bility [12]. The imbalance between high initial solubilized drug concentrations and lower
equilibrium drug solubilities during lipid dispersion and digestion in vivo does not immedi‐
ately result in precipitation but stimulates drug supersaturation. This supersaturation is more
likely to occur in the formulations that contain high proportions of water soluble surfactants
or cosolvent. In some cases, during the process of lipid (or surfactant) digestion where
hydrolysis occurs to form more polar post digestion products also stimulates changes to
colloidal structure, thus lead to changes in drug solubility and may facilitate drug precipita‐
tion.
This is why, SNEDDS must contain drugs less than equilibrium solubility (approximately 50–
90% of the equilibrium solubility) to avoid any precipitation. In recent studies, precipitation
inhibitors have been introduced in supersaturated SNEDDS to overcome the risk of precipi‐
tations [40]. Supersaturated SNEDDS inhibit and minimize the nucleation process and
subsequent drug precipitation in GIT by achieving and then sustaining the metastable
supersaturated state. The commonly used water soluble precipitation inhibitors are PVP,
HPMC, NaCMC and MC polymers [41].
7.1. The risk of drug precipitation from nanoformulations
Triglycerides alone (LFCS Type I) are poor solvents for most of the hydrophobic drugs but
suitable for highly lipophilic compounds. If lipid‐based formulations contain mixed glycer‐
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ides, polar oils, surfactants and/or cosolvents (LFCS Type II and III), it is likely to improve the
solvent capacity of the formulation. Therefore, formulators are always preferred to add water
soluble surfactants and cosolvents against pure oils, ultimately sometimes resulting in the
complete exclusion of oily excipients to produce oil‐free formulations (LFCS Type IV).
However, the formulator must keep well balance between oils and surfactants/cosolvents in
the formulation to avoid risk of drug precipitation on aqueous dispersion. Several studies
showed that small changes in formulation compositions are not expected to cause large
changes in drug solubility, but there could be a dramatic drop in solvent capacity upon aqueous
dilution [4, 12, 42]. Dilution of a cosolvent implies a substantial loss of solvent capacity, while
the loss of solvent capacity may not be suffered with the use of surfactant. This could be
possible due to the linearity between solubilized drug to the number of micelles present and
therefore to the surfactant concentration. Drugs which are more soluble in surfactant or
cosolvent than pure oil are at high precipitation risk because solvent capacity of surfactant and
cosolvent decreases upon dilution but not pure oil. Hence, increasing the solubility of a drug
by including a cosolvent is generally a poor strategy than using a nonionic surfactant [11, 43].
Figure 4 shows the extreme precipitation of an anticancer drug, paclitaxel using LFCS Types
III and IV formulations.
Figure 4. Percentage of the original dose of paclitaxel remaining in solution after 1:100 dilutions in the dispersion me‐
dium (paclitaxel was originally dissolved at 80% of the equilibrium solubility in the anhydrous mixture). One gram
formulation was dispersed in 100 ml water, and then, the samples were withdrawn periodically over 24 h to examine
the drug precipitations. Data are presented as mean ± SD (n = 3).
It is quite difficult to predict the fate of the PWSDs on dispersion of a typical LFCS Type IIIA
lipid formulation. The hydrophilic surfactant used in Type IIIA systems is substantially
separated from the oily components, forming a micellar solution in the continuous phase.
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Hence, one might question: does this system lower the overall solvent capacity for the drug or
not? However, this may depend on the log P of the drug, and to what extent the surfactant was
contributing to its solubilization within the formulation. At present, there are no established
techniques available to help formulators assessing the risk of precipitation. It is worth men‐
tioning that in some cases, Type III formulations can take several days to reach equilibrium
and the drug remains in a supersaturated state for up to 24 h time [12]. It could be argued that
such formulations are not likely to cause precipitation in the gut before the drug is absorbed,
and possibly the supersaturation acts as an absorption enhancer by increasing the thermody‐
namic stability of the drug [44].
8. Lipid digestion and drug absorption: mechanism
8.1. Lipid metabolism
Following ingestion of a lipid‐based dosage form (capsule/tablet), the formulation is initially
dispersed in the stomach where the digestion of exogenous dietary lipid is started by the action
of gastric lipase on the lipid‐water interface. Gastric lipase releases about 15% of free fatty acids
from lipids [45]. Within the small intestine, pancreatic lipase together with its co‐lipase
completes the breakdown of dietary glycerides to diglyceride, monoglyceride and fatty acid.
The presence of exogenous lipids in the small intestine also stimulates secretion of endogenous
biliary lipids including bile salt, phospholipid and cholesterol from the gallbladder [45]. In the
presence of elevated bile salts concentrations, lipid digestion products are subsequently
incorporated into a series of colloidal structures including multilamellar/unilamellar vesicles,
bile salt phospholipid mixed micelles and micelles [46]. Together these species significantly
expand the solubilization capacity of the small intestine for both lipid digestion products and
drugs, and this can be studied relatively easily as a preformulation exercise.
8.2. Drug absorption
Sufficient aqueous solubility along with good intestinal permeability is crucial for adequate
drug absorption, ultimately leading to sufficient bioavailability. On the other hand, PWSDs are
associated with poor and variable absorption and often affected by the various food intakes.
Several studies have already documented lipid‐based nanoformulations, particularly
SNEDDS, as an absorption enhancer for PWSDs when administered orally [4, 47]. Possible
mechanisms for improving drug absorption include: (i) an increase in the membrane fluidity
facilitating transcellular absorption, (ii) larger surface area provided by the fine emulsion
droplets, hydrolysis and formation of mixed micelles, (iii) paracellular transport by opening
tight junction mainly for ionized drugs or hydrophilic macromolecules, (iv) inhibition of P‐gp
and/or CYP450 to increase intracellular concentration and residence time, and (v) stimulation
of lipoprotein/chylomicron production. The natural process of digestion offers the possibility
that very lipophilic drugs could be taken up into the lymphatic system by partitioning into
chylomicrons in the mesentery. This is expected to be a mechanism of absorption for drugs
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with log P values >6.0 and has been demonstrated to be crucial in a past study for the absorption
of the antimalarial compound halofantrine [48, 49].
The mixed micelles substantially transport digestion products across the unstirred water layer
and reach the vicinity of the aqueous‐microvillus interface to allow for lipid absorption
through the mucosal cells. However, it is possible that digestion of a lipid formulation could
reduce the solubility of the drug in the gut lumen, which would result in the precipitation of
the drug and a decrease in the absorption rate. Therefore, more investigation on in vitro
lipolysis is needed to clearly understand drug precipitation during digestion for better
absorption.
9. In vitro digestion (lipolysis): significance
The fate of the lipid carrier in the GI tract is essentially important for the absorption of the
incorporated drug and therefore has to be closely analyzed. It is evident that the solvent
capacity of the formulation can be lost on digestion, leading to drug precipitation [26, 50].
However, the investigation of the lipolysis by in vivo experiments is complex, costly and time‐
consuming. Thus, the in vitro model simulating the enzymatic degradation of lipid‐based
formulations is highly significant as an alternative method of monitoring the digestion process
in the simulated gastrointestinal media under fed and fasted conditions.
Lipolysis can be carried out as an in vitro test using a pH‐stat titration unit to maintain pH and
using the lipase/co‐lipase content of porcine pancreatin to serve as model for human pancreatic
juice. Bile salt lecithin‐mixed micelles are used in the reaction mixture to provide a sink for
solubilization of degradation products. Composition of mixture that used in the in vitro
lipolysis studies is provided in Table 2.
Substance of the mixture for 10 ml aqueous media
Lipid 250 mg
Pancreatic lipase 1 ml (800 TBU/ml)
Lipolysis buffer 9 ml
Composition of the lipolysis buffer Concentration (fed state) Concentration (fasted state)
Bile salt (BS, mM) 20 5
Phospholipid (PL, mM) 5 1.25
Trizma maleate (mM) 0.5 0.5
Ca+ (mM) 0.05 0.05
Na+ (mM) 1.5 1.5
Table 2. Composition of mixture for in vitro lipolysis experiments. *Adapted with permission from Ref. [51].
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Lipolysis is allowed to proceed for a fixed time (30–60 min), the reaction is then subjected to
high‐speed ultracentrifugation, and further drug analysis in the various phases allows
predicting whether the drug will remain solubilized in the intestinal lumen after digestion of
the formulation. However, if the drug is partially precipitated, then drug will be found in the
pellet, which may be still in solution. The rate and extent of lipolysis can be quantified by the
data generated from the pH‐stat. This technique was recently applied in LFCS Types I–IV
formulations to predict the effect of formulation on the fate of a number of drug compounds
and assumed that surfactants are subjected to digestion, probably for SMEDDS and SNEDDS,
where water soluble surfactants are used predominantly. Lipolysis experiments may play a
vital role in the near future for establishing strong methods for in vitro in vivo correlations
(IVIVCs).
10. In vitro in vivo correlation (IVIVC) for lipid nanoformulations
The IVIVCs play a major role in drug development, particularly on the optimization of suitable
formulations which is time‐consuming and a highly expensive process. Formulation optimi‐
zation requires modifications in composition, equipment, manufacturing process and batch
sizes. If such changes applied to the formulation, the in vivo bioequivalence studies in human
are necessary to be conducted to confirm the similarity of the new formulation. This process
will increase the load of carrying out a number of bioequivalence studies and therefore will
increase the cost of process optimization and marketing of the new formulation.
To overcome these issues, it is necessary to develop in vitro tests that can imitate the bioavail‐
ability data. The IVIVC can be used in the development of new pharmaceuticals to decrease
the number of human trials during the formulation development and to support biowaivers.
In the beginning of 1980s, the IVIVC theory was established based on many published research
studies, which can be used as a prediction tool for correlating in vitro and in vivo data. The
IVIVC is usually used in the development stages of pharmaceuticals to enhance the formulation
and dosage optimization with fewer trials in human [51–56] or additional bioavailability
studies. The FDA defines IVIVC as “a predictive mathematical model describing the relation‐
ship between an in vitro property of a dosage form (usually the rate or extent of drug dissolution
or release) and a relevant in vivo response (e.g., plasma drug concentration or amount of drug
absorbed).” For drugs that are administered orally, dissolution and intestinal permeation are
considered as the rate‐limiting steps for the absorption. Therefore, if an excellent correlation
exists between in vitro dissolution test and a bioavailability parameter, then controlling the
dissolution profile will permit the evaluation of bioavailability [57–59].
There are several tools which can be used to establish IVIVC. The in vitro drug release studies
of the formulations can be performed using dissolution, dynamic dispersion and digestion
tests, whereas the in vivo pharmacokinetic studies can be performed on various animal models.
However, there are only a limited number of IVIVC studies so far have been conducted using
lipid formulations. To obtain more robust in vitro and in vivo relationship, a large number of
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model compounds should be explored along with more human clinical data sets and complete
characterizations of in vitro and in vivo solubilization of PWSDs formulated in lipid vehicles.
11. Conclusion
For many drugs with poor aqueous solubility, the technique of developing SMEDDS/SNEDDS
provides a powerful and effective solution to improve their solubility in the aqueous contents
of the GI tract that is the main obstacle for such drugs. The most critical step in designing the
nanoformulations of lipid‐based systems for PWSDs is the selection of the most suitable oil,
surfactant and/or cosolvent for a particular drug with certain physicochemical properties. So,
the formulators must keep a balance and make compatibility between the factors of different
formulations such as self‐emulsification efficiency, drug loading capacity, droplet size distri‐
bution, in vitro dispersion/release profile in acidic and basic media and in vitro digestion by
using fed and fasted state. In summary, SMEDDS/SNEDDS provide a robust formulation
approach to enhance GI solubilization and to promote drug absorption after oral administra‐
tion. If there is a successful IVIVC made for lipid nanoformulations, confidence in the devel‐
opment of the pharmaceutical product and its quality are likely to improve, and the drug
development time may be shortened.
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